---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-25-000079"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:58:19.073829+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Instil Bio Q2 net loss $3.24/share; cash $103.6M; IND cleared for '2510

## Summary
- Cash, equivalents, marketable securities and long-term investments of $103.6M as of June 30, 2025; funded beyond 2026.
- Net loss per share $3.24 (GAAP) and $2.88 (non-GAAP) for Q2 2025, vs $2.29 and $1.57 year-ago.
- R&D expenses $6.7M in Q2 2025; in-process R&D expenses $10.0M; G&A expenses $6.2M.
- U.S. IND for AXN-2510/IMM2510 cleared; U.S. trial initiation expected before end of 2025.
- Appointed Jamie Freedman, M.D., Ph.D. as Chief Medical Officer in June 2025.

## SEC filing metadata
- accession: 0001789769-25-000079
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000079/0001789769-25-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000079/til-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-25-000079
- JSON: https://secwatch.observer/filing/0001789769-25-000079.json
- Plain text: https://secwatch.observer/filing/0001789769-25-000079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.